CD155 reprograms glycolysis via the YAP/TEAD1-GLUT1 axis to promote lung adenocarcinoma progression and M2 macrophage polarization: a metabolic-immune target visualized by 18F-FDG PET/CT
We identify a novel CD155/YAP/TEAD1/GLUT1 axis that reprograms LUAD metabolism and facilitates immunosuppressive tumor microenvironment formation. CD155 functions as a metabolic-immune hub in LUAD, and its targeting could simultaneously suppress tumor growth and restore antitumor immunity, offering dual therapeutic advantages. Clinically, <sup>18</sup>F-FDG PET/CT represents a noninvasive biomarker for CD155-driven metabolic aggression, potentially guiding precision immunotherapy.
Authors
- Shu Wang (ORCID: https://orcid.org/0000-0003-1734-9770)
- Yuxiang Wang (ORCID: https://orcid.org/0009-0009-3914-4486)
- Bulin Du
- Shuoyan Xu (ORCID: https://orcid.org/0000-0003-0682-4281)
- Zhiming Cheng (ORCID: https://orcid.org/0000-0002-3032-0764)
- Yao Diao
- XueNa Li
- Yaming Li
Institutions
- First Hospital of China Medical University (CN)
- China Medical University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1186/s12967-025-07551-7
- Primary Topic
- Hippo pathway signaling and YAP/TAZ
- Type
- article
- Field-Weighted Citation Impact
- 0.00